World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 19 April 2022
Main ID:  EUCTR2016-001979-70-NL
Date of registration: 23/11/2016
Prospective Registration: Yes
Primary sponsor: Inventiva S.A.
Public title: A randomized, double-blind, placebo-controlled, multicenter, dose-range, proof-of-concept, 24-week treatment study of IVA337 in adult subjects with nonalcoholic steatohepatitis (NASH)
Scientific title: A randomized, double-blind, placebo-controlled, multicenter, dose-range, proof-of-concept, 24-week treatment study of IVA337 in adult subjects with nonalcoholic steatohepatitis (NASH)
Date of first enrolment: 19/02/2018
Target sample size: 300
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-001979-70
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 3
 
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no
Countries of recruitment
Australia Austria Belgium Bulgaria Czech Republic France Germany Italy
Netherlands Poland Portugal Slovenia Spain Switzerland United Kingdom
Contacts
Name: Project Manager, ABELLO Nicolas   
Address:  50, Rue de Dijon 21121 Daix France
Telephone: +330380 447 593
Email: nicolas.abello@inventivapharma.com
Affiliation:  INVENTIVA S.A.
Name: Project Manager, ABELLO Nicolas   
Address:  50, Rue de Dijon 21121 Daix France
Telephone: +330380 447 593
Email: nicolas.abello@inventivapharma.com
Affiliation:  INVENTIVA S.A.
Key inclusion & exclusion criteria
Inclusion criteria:
-Adult subjects, age =18 years.
-NASH histological diagnosis according to the currently accepted definition of both EASL and AASLD (1–3), requiring the combined presence of steatosis (any degree = 5%) + lobular inflammation of any degree + liver cell ballooning of any amount, on a liver biopsy performed = 6 months before screening in the study and confirmed by central reading during the screening period and
a.SAF Activity score of 3 or 4 (>2)
b.SAF Steatosis score = 1
c.SAF Fibrosis score: < 4
-Subject agrees to have a liver biopsy performed after 24 weeks of treatment
-Compensated liver disease with the following hematologic and biochemical criteria on entry into protocol:
oALT < 10N
oHemoglobin > 11 g/dL for females and > 12 g/dL for males
oWhite blood cell (WBC) > 2.5 K/µL
oNeutrophil count > 1.5 K/µL
oPlatelets > 100 K/µL
oTotal bilirubin < 35µmol/L. Patients with bilirubin > 35µmol/L can be included if non-conjugated bilirubin in the setting of a Gilbert syndrome.
oAlbumin > 36 g/L
oTP > 80% or INR > 1.4
oSerum creatinin <1.3 mg/dL (men) or <1.1 (women) or estimated glomerular filtration rate = 60 mL/min/1.73m2
-No other cause of chronic liver disease (autoimmune, primary biliary cholangitis, HBV, HCV, Wilson’s, a-1-antitrypsin deficiency, hemochromatosis etc…)
-If applicable, have a stable type 2 diabetes, defined as HgbA1c < 8.5% and fasting glycemia <10 mmol/L, no changes in medication in the previous 6 months, and no new symptoms associated with decompensated diabetes in the previous 3 months.
-Have a stable weight since the liver biopsy was performed defined by no more than a 5 % loss of initial body weight
-Negative pregnancy test or post-menopausal. Women with childbearing potential (i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile) must be using a highly effective method of contraception (i.e. combined (estrogen and progestogen containing) hormonal/ progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner, sexual abstinence).
-Subjects must be willing to give written informed consent.

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 270
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 30

Exclusion criteria:
-Evidence of another form of liver disease.
-History of sustained excess alcohol ingestion: daily alcohol consumption > 30 g/day (3 drinks per day) for males and > 20 g/day (2 drinks/day) for females.
-Unstable metabolic condition: Weight change > 5kg in the last three months, diabetes with poor glycemic control (HgbA1c > 8.5%), introduction of an antidiabetic or of an anti-obesity drug/malabsorptive or restrictive bariatric (weight loss) surgery in the past 6 months prior to screening.
-History of gastrointestinal malabsorptive bariatric surgery within less than 5 years or ingestion of drugs known to produce hepatic steatosis including corticosteroids, high-dose estrogens, methotrexate, tetracycline or amiodarone in the previous 6 months.
-Significant systemic or major illnesses other than liver disease, including congestive heart failure (class C and D of the AHA), unstable coronary artery disease, cerebrovascular disease, pulmonary disease, renal failure, organ transplantation, serious psychiatric disease, malignancy that, in the opinion of the investigator, would preclude treatment with IVA337 and/or adequate follow up.
-HB antigen >0, HCV PCR >0 (patients with a history of HCV infection can be included if HCV PCR is negative since more than 3 years), HIV infection.
-Pregnancy/lactation or inability to adhere to adequate contraception in women of child-bearing potential.
-Active malignancy except cutaneous basocellular carcinoma.
-Any other condition which, in the opinion of the investigator would impede competence or compliance or possibly hinder completion of the study
-Body mass index (BMI) >45 kg/m2.
-Type 1 diabetes.
-Diabetic ketoacidosis
-Fasting Triglycerides > 300 mg/dL.
-Hemostasis disorders or current treatment with anticoagulants.
-Contra-indication to liver biopsy.
-History of, or current cardiac dysrhythmias and / or a history of cardiovascular disease, including myocardial infarction, except patients with only well controlled hypertension.
-Participation in any other investigational drug study within the previous 3 months.
-Have a known hypersensitivity to any of the ingredients or excipients of the IMP.
-Be possibly dependent on the Investigator or the Sponsor (eg, including, but not limited to, affiliated employee).



Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Nonalcoholic steatohepatitis (NASH)
MedDRA version: 19.0 Level: PT Classification code 10053219 Term: Non-alcoholic steatohepatitis System Organ Class: 10019805 - Hepatobiliary disorders
Intervention(s)

Product Name: IVA337
Product Code: IVA337
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Not Available
CAS Number: 927961-18-0
Current Sponsor code: IVA337
Other descriptive name: 1-(6-BENZOTHIAZOLYLSULFONYL)-5-CHLORO-1H-INDOLE-2-BUTANOIC ACID
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 400-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use

Primary Outcome(s)
Secondary Objective: Pharmacokinetics.
Main Objective: To assess the safety and the efficacy on the activity part of the Steatosis Activity Fibrosis histological score (inflammation and ballooning) of a 24-week treatment with two doses of IVA337 (800, 1200 mg/24h) in NASH adult patients.
Primary end point(s): The primary endpoint is a binary outcome (responder / non responder). A responder is defined as a decrease from baseline to week 24 of at least 2 points of the SAF activity score combining hepatocellular inflammatory and ballooning score without fibrosis progression. Responder rates will be compared between the placebo and IMP groups at the end of the treatment period (week 24) using a Cochran Mantel Haenzel test stratified on diabetes.
Timepoint(s) of evaluation of this end point: At the end of the treatment period (week 24)
Secondary Outcome(s)
Timepoint(s) of evaluation of this end point: From baseline to 24 weeks of treatment
Secondary end point(s): The following changes from baseline to 24 weeks of treatment will be evaluated:
•NASH improvers defined as subjects with a decrease of at least 2 points in NAS, and no worsening in fibrosis in NASH from baseline to end of treatment (week 24).
•Percent of patients with reversal of NASH (Steatosis without ballooning and with or without mild inflammation and no worsening of fibrosis) from baseline to end of treatment (week 24).
•Percent of patients with a change in components of SAF score from baseline to end of treatment (week 24):
-Steatosis: -1 point
-Lobular inflammation: -1 point
-Balloonning: -1 point
•Immunohistochemistry: change in the semiquantitative score of ballooning and stellate cell activation from baseline to end of treatment (week 24).
•Change in fibrosis score on a 4-point scale (SAF) and modified Ishak: - 1 point from baseline to end of treatment (week 24). Comparison of mean change in fibrosis area assessed by morphometry (CPA) from baseline to end of treatment (week 24).
•Liver enzymes (ALT, AST, ?GT) change from baseline to end of treatment (week 24).
•Inflammatory markers (fibrinogen, hs-CRP, alpha2 macroglobulin and haptoglobin levels) change from baseline to end of treatment (week 24).
•Glucose metabolism (fasting glucose and insulin, HOMA index and, in subjects with T2DM, HbA1c) change from baseline to end of treatment (week 24).
•Main plasma lipids levels (TC, HDL-C, calculated LDL-C, TG and apoA1) change from baseline to end of treatment (week 24).
•Adiponectin change from baseline to end of treatment (week 24).
Secondary ID(s)
2016-001979-70-BE
IVA_01_337_HNAS_16_002
Source(s) of Monetary Support
Inventiva S.A.
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date: 19/02/2018
Contact:
Results
Results available: Yes
Date Posted: 01/04/2021
Date Completed: 16/03/2020
URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001979-70/results
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history